AMED Analyst Estimates: Price Targets, Revenue, Net Income, and EBIT Forecast - Amedisys Inc - Alpha Spread

First Time Loading...

Watchlist Manager

Watchlist

Price: 91.84 USD 0.05%

Updated:

Section:

Wall Street
Price Targets

Wall Street analysts forecast AMED stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AMED is 99.73 USD with a low forecast of 73.73 USD and a high forecast of 106.05 USD.

AMED Lowest Forecast

Wall Street Target

AMED Average Forecast

Wall Street Target

AMED Highest Forecast

Wall Street Target

20% Downside

9% Upside

15% Upside

The latest public price target was made on Mar 25, 2024 by Frank Morgan from RBC Capital , who expects AMED stock to rise by 9% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst	Price Target	Date	Article
Frank Morgan RBC Capital	100 USD Upside 9%	1 month ago Mar 25, 2024	Amedisys (AMED) PT Raised to $100 at RBC Capital StreetInsider
Brian Tanquilut Jefferies	90.8 USD Downside 1%	9 months ago Jul 6, 2023	Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday Benzinga

Price Target	100 USD
Upside/Downside	9%

Price Target	90.8 USD
Upside/Downside	1%

Arrail Group Ltd

53% Upside

Enhabit Inc

8% Upside

Euroeyes International Eye Clinic Ltd

112% Upside

Krsnaa Diagnostics Ltd

69% Upside

Arrail Group Ltd

53% Upside

Enhabit Inc

8% Upside

Euroeyes International Eye Clinic Ltd

112% Upside

Krsnaa Diagnostics Ltd

69% Upside

Fleury SA

38% Upside

Guardant Health Inc

119% Upside

Gushengtang Holdings Ltd

43% Upside

Talkmed Group Ltd

57% Upside

Revenue
Forecast

For the last 8 years the compound annual growth rate for Amedisys Inc's revenue is 7%. The projected CAGR for the next 3 years is 6%.

7%

6%

-2%

What are analyst estimates?

Operating Income
Forecast

For the last 8 years the compound annual growth rate for Amedisys Inc's operating income is 14%. The projected CAGR for the next 3 years is 9%.

14%

9%

-11%

What are analyst estimates?

Net Income
Forecast

N/A

N/A

-13%

What are analyst estimates?

See Also

Relative Valuation

Wall Street Estimates

Profitability Analysis

Solvency Analysis

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

According to Wall Street analysts, the average 1-year price target for AMED is 99.73 USD with a low forecast of 73.73 USD and a high forecast of 106.05 USD.

For the last 8 years the compound annual growth rate for Amedisys Inc's revenue is 7%. The projected CAGR for the next 3 years is 6%.

For the last 8 years the compound annual growth rate for Amedisys Inc's operating income is 14%. The projected CAGR for the next 3 years is 9%.

Join more than 132,700+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.